235 related articles for article (PubMed ID: 28248857)
41. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
Wang R; Dasgupta A; Ward MM
J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
[TBL] [Abstract][Full Text] [Related]
42. [Comparison of clinical manifestations according to HLA-B(27) genotype in ankylosing spondylitis patients: real-world evidence from smart management system for spondyloarthritis].
Ji XJ; Sun K; Hu ZY; Zhang Y; Ma YP; Sun Z; Li KP; Zhu J; Zhang JL; Huang F
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):179-184. PubMed ID: 29518861
[No Abstract] [Full Text] [Related]
43. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
44. CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis.
Siebuhr AS; Bay-Jensen AC; Karsdal MA; Lories RJ; de Vlam K
Biomark Med; 2016; 10(2):197-208. PubMed ID: 26764293
[TBL] [Abstract][Full Text] [Related]
45. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
46. A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients.
Yang R; Liu H; Fan M
Medicine (Baltimore); 2019 Mar; 98(11):e14620. PubMed ID: 30882628
[TBL] [Abstract][Full Text] [Related]
47. Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy.
Sun CJ; Li L; Li XY; Zhang WY; Liu XW
Arch Gynecol Obstet; 2018 Jul; 298(1):125-132. PubMed ID: 29789925
[TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of Jitongning Capsule () in patients with ankylosing spondylitis.
Wang YY; Lu H; Zhao Z; Huang F
Chin J Integr Med; 2013 Feb; 19(2):98-103. PubMed ID: 23371457
[TBL] [Abstract][Full Text] [Related]
49. Genetic polymorphisms of stromal interaction molecule 1 associated with the erythrocyte sedimentation rate and C-reactive protein in HLA-B27 positive ankylosing spondylitis patients.
Wei JC; Hung KS; Hsu YW; Wong RH; Huang CH; Jan MS; Wu SJ; Juan YS; Chang WC
PLoS One; 2012; 7(12):e49698. PubMed ID: 23272049
[TBL] [Abstract][Full Text] [Related]
50. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
51. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.
Lee SH; Lee YA; Hong SJ; Yang HI
Clin Rheumatol; 2008 Feb; 27(2):179-81. PubMed ID: 17874173
[TBL] [Abstract][Full Text] [Related]
52. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.
Yates M; Hamilton LE; Elender F; Dean L; Doll H; MacGregor AJ; Thomas J; Gaffney K
J Rheumatol; 2015 Jul; 42(7):1177-85. PubMed ID: 26034151
[TBL] [Abstract][Full Text] [Related]
53. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
54. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
[TBL] [Abstract][Full Text] [Related]
55. Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial.
Rusman T; van der Weijden MAC; Nurmohamed MT; Landewé RBM; de Winter JJH; Boden BJH; Bet PM; van der Bijl CMA; van der Laken C; van der Horst-Bruinsma IE
Arthritis Rheumatol; 2021 May; 73(5):806-815. PubMed ID: 33277982
[TBL] [Abstract][Full Text] [Related]
56. Gender difference in ASAS HI among patients with ankylosing spondylitis.
Chen HH; Chen YM; Lai KL; Hsieh TY; Hung WT; Lin CT; Tseng CW; Tang KT; Chou YY; Wu YD; Huang CY; Hsieh CW; Huang WN; Chen YH
PLoS One; 2020; 15(7):e0235678. PubMed ID: 32645080
[TBL] [Abstract][Full Text] [Related]
57. Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population.
Li J; Wang X; Han Z; Zhang Y; Wang Y; Zhang Y; Li W
Int J Immunopathol Pharmacol; 2016 Sep; 29(3):510-5. PubMed ID: 27381286
[TBL] [Abstract][Full Text] [Related]
58. Genetic variations in the IL-12B gene in association with IL-23 and IL-12p40 serum levels in ankylosing spondylitis.
Ivanova M; Manolova I; Miteva L; Gancheva R; Stoilov R; Stanilova S
Rheumatol Int; 2019 Jan; 39(1):111-119. PubMed ID: 30443744
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
[TBL] [Abstract][Full Text] [Related]
60. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
